Callisto Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The company s lead drug candidates comprise Plecanatide, a guanylyl cyclase C (GC-C) receptor agonist, to treat GI disorders, primarily chronic constipation and constipation-predominant irritable bowel syndrome; and SP-333, a second generation GC-C receptor agonist, which is in pre-clinical development to treat gastrointestinal inflammatory diseases. It develops plecanatide, which under Phase II/III clinical trials and is intended for the treatment of chronic idiopathic constipation. The company was founded in 1996 and is headquartered in New York, New York.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• No BuyIns.Net Alerts Available for CLSP